48. Primary antiphospholipid syndrome Clinical trials / Disease details


Clinical trials : 5 Drugs : 6 - (DrugBank : 4) / Drug target gene : 1 - Drug target pathways : 7

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05671757
(ClinicalTrials.gov)
March 12, 202320/12/2022Daratumumab in Primary Antiphospholipid SyndromeTargeting CD38 With Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial (ITN093AI)Autoimmune DisordersBiological: DaratumumabNational Institute of Allergy and Infectious Diseases (NIAID)Immune Tolerance Network (ITN);PPD;Rho Federal Systems Division, Inc.Not yet recruiting18 Years65 YearsAll22Phase 1/Phase 2United States
2NCT05078710
(ClinicalTrials.gov)
July 1, 202124/9/2021Telitacicept in Primary APS PatientsA Pilot Study of Telitacicept Treatment in Primary APS PatientsAnti Phospholipid SyndromeDrug: TelitaciceptPeking Union Medical College HospitalNULLRecruiting18 Years65 YearsAll20Phase 2China
3NCT03540810
(ClinicalTrials.gov)
August 15, 201827/4/2018Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid SyndromeHydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid SyndromePrimary Antiphospholipid SyndromeDrug: Hydroxychloroquine;Drug: PlaceboUniversity Hospital, AngersNULLNot yet recruiting18 YearsN/AAll300Phase 3France
4NCT01956188
(ClinicalTrials.gov)
May 201425/9/2013Omega 3 in LES and APSEfficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid SyndromeSystemic Lupus Erythematosus;Primary Antiphospholipid SyndromeDietary Supplement: EPA and DHA supplementation;Dietary Supplement: PlaceboUniversity of Sao PauloNULLActive, not recruiting20 Years45 YearsFemale22N/ABrazil
5NCT04153201
(ClinicalTrials.gov)
January 15, 201321/10/2019Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid SyndromeEffect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study.Antiphospholipid SyndromeDrug: HydroxychloroquineNational and Kapodistrian University of AthensNULLCompleted18 YearsN/AAll50N/AGreece